Forte Capital LLC ADV Trims Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Forte Capital LLC ADV decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 31.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,081 shares of the medical research company’s stock after selling 12,558 shares during the quarter. Forte Capital LLC ADV’s holdings in IQVIA were worth $5,322,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in IQV. FMR LLC increased its stake in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in IQVIA during the third quarter worth $147,683,000. JPMorgan Chase & Co. increased its stake in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Nordea Investment Management AB increased its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Finally, KBC Group NV increased its stake in IQVIA by 68.5% during the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock worth $121,109,000 after acquiring an additional 250,458 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Activity

In other news, Director John G. Danhakl bought 1,275 shares of IQVIA stock in a transaction dated Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Down 1.3 %

Shares of NYSE IQV opened at $194.01 on Friday. The company has a market capitalization of $34.16 billion, a price-to-earnings ratio of 25.87, a price-to-earnings-growth ratio of 2.01 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The business has a 50-day moving average of $199.86 and a two-hundred day moving average of $216.95. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts forecast that IQVIA Holdings Inc. will post 10.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on IQV. TD Cowen cut their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Stephens started coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Robert W. Baird dropped their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. Finally, Truist Financial reaffirmed a “buy” rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $251.22.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.